[
  {
    "ts": null,
    "headline": "LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price Pressures",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=6fab3abb5e2ceaa0a67c1ec720bf65466ed274c3fe5a86764c96a3cd50cc5926",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747261919,
      "headline": "LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price Pressures",
      "id": 134465641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=6fab3abb5e2ceaa0a67c1ec720bf65466ed274c3fe5a86764c96a3cd50cc5926"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. Attacks Health Agency, Defends Cuts Before Congress",
    "summary": "(Bloomberg) -- Health and Human Services Secretary Robert F. Kennedy Jr. defended cutting thousands of staff and attacked the agency’s past work in his first day appearing before Congress since taking the nation’s top health role.Most Read from BloombergAs Coastline Erodes, One California City Considers ‘Retreat Now’How a Highway Became San Francisco’s Newest ParkPower-Hungry Data Centers Are Warming Homes in the NordicsA New Central Park Amenity, Tailored to Its East Harlem NeighborsMaryland’s",
    "url": "https://finnhub.io/api/news?id=fd12a24476958d9b70358ba3bb1ffef31076954719a05a3d2528a9c6d89fd2df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747258184,
      "headline": "RFK Jr. Attacks Health Agency, Defends Cuts Before Congress",
      "id": 134460710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Health and Human Services Secretary Robert F. Kennedy Jr. defended cutting thousands of staff and attacked the agency’s past work in his first day appearing before Congress since taking the nation’s top health role.Most Read from BloombergAs Coastline Erodes, One California City Considers ‘Retreat Now’How a Highway Became San Francisco’s Newest ParkPower-Hungry Data Centers Are Warming Homes in the NordicsA New Central Park Amenity, Tailored to Its East Harlem NeighborsMaryland’s",
      "url": "https://finnhub.io/api/news?id=fd12a24476958d9b70358ba3bb1ffef31076954719a05a3d2528a9c6d89fd2df"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal",
    "summary": "Lilly Pullback Follows $2.2B Obesity Licensing Deal by Novo?Nordisk",
    "url": "https://finnhub.io/api/news?id=cbecd10825f848378dc133a2db5ed91d6725055745ed4e0bece292178effabbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747257626,
      "headline": "Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal",
      "id": 134460711,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly Pullback Follows $2.2B Obesity Licensing Deal by Novo?Nordisk",
      "url": "https://finnhub.io/api/news?id=cbecd10825f848378dc133a2db5ed91d6725055745ed4e0bece292178effabbc"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare worst-performing S&P 500 subsector year to date: Mizuho expert",
    "summary": "Tariffs, executive orders, and FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's actions are pressuring a historically \"safe\" sector.",
    "url": "https://finnhub.io/api/news?id=4cb69af4c2b40b9be1f2c907518b3daa766aee160dfc1a2e708c1300eaafcce8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747238373,
      "headline": "Healthcare worst-performing S&P 500 subsector year to date: Mizuho expert",
      "id": 134460712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tariffs, executive orders, and FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's actions are pressuring a historically \"safe\" sector.",
      "url": "https://finnhub.io/api/news?id=4cb69af4c2b40b9be1f2c907518b3daa766aee160dfc1a2e708c1300eaafcce8"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Rises on Weight-Loss News. It’s a Huge Deal for This Stock.",
    "summary": "The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain competitive.",
    "url": "https://finnhub.io/api/news?id=9bbc08b1008d791d12d5a7ce0d66c78e7016063d8220ebb4e663ae3877c88df7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747232880,
      "headline": "Novo Nordisk Rises on Weight-Loss News. It’s a Huge Deal for This Stock.",
      "id": 134460713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain competitive.",
      "url": "https://finnhub.io/api/news?id=9bbc08b1008d791d12d5a7ce0d66c78e7016063d8220ebb4e663ae3877c88df7"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”",
    "summary": "We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued […]",
    "url": "https://finnhub.io/api/news?id=6c6ae69793102b77bf0b292ce5cdfacd3677969dd6ce6d0b4fc1cc8cc5ee4f33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747232199,
      "headline": "Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”",
      "id": 134460714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued […]",
      "url": "https://finnhub.io/api/news?id=6c6ae69793102b77bf0b292ce5cdfacd3677969dd6ce6d0b4fc1cc8cc5ee4f33"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna",
    "summary": "Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.",
    "url": "https://finnhub.io/api/news?id=71b06c9802ba32c3efeb1275638679d3b784e16acd1c56670b59adf5f109f919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747229552,
      "headline": "Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna",
      "id": 134460715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.",
      "url": "https://finnhub.io/api/news?id=71b06c9802ba32c3efeb1275638679d3b784e16acd1c56670b59adf5f109f919"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?",
    "summary": "Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
    "url": "https://finnhub.io/api/news?id=6fda579e3f818909bf5be41f1b3500d1dd85fd49275ceb5cbb5e6f68d8ebad0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747227060,
      "headline": "Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?",
      "id": 134460716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
      "url": "https://finnhub.io/api/news?id=6fda579e3f818909bf5be41f1b3500d1dd85fd49275ceb5cbb5e6f68d8ebad0b"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For May",
    "summary": "This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Read the full analysis here on Seeking Alpha, updated for May 2025.",
    "url": "https://finnhub.io/api/news?id=6034d561f5dd4a27632eead6ab25b5a039e4bdb6720041cd8cd9e718132da992",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747223425,
      "headline": "IXJ: Healthcare Sector Dashboard For May",
      "id": 134437816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356518831/image_1356518831.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Read the full analysis here on Seeking Alpha, updated for May 2025.",
      "url": "https://finnhub.io/api/news?id=6034d561f5dd4a27632eead6ab25b5a039e4bdb6720041cd8cd9e718132da992"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "summary": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
    "url": "https://finnhub.io/api/news?id=8ab9dcccbd821b4af88441cd016dbca2988656c853d954eedc4541b773e0ce23",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747218240,
      "headline": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "id": 134437591,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.",
      "url": "https://finnhub.io/api/news?id=8ab9dcccbd821b4af88441cd016dbca2988656c853d954eedc4541b773e0ce23"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
    "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747212240,
      "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
      "id": 134435565,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166679764/image_2166679764.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
      "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Global Impact Fund Q1 2025 Commentary",
    "summary": "The Hartford Global Impact Fund (I Share) outperformed the MSCI ACWI Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=2b71041fce234f403899e6b2b7556c5b2fce8103e275b2884515cf74b32bbcd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747184280,
      "headline": "Hartford Global Impact Fund Q1 2025 Commentary",
      "id": 134431611,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1817128859/image_1817128859.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Global Impact Fund (I Share) outperformed the MSCI ACWI Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=2b71041fce234f403899e6b2b7556c5b2fce8103e275b2884515cf74b32bbcd2"
    }
  }
]